Cell Death and Disease (May 2022)

Sex differences in global metabolomic profiles of COVID-19 patients

  • Rocio Diaz Escarcega,
  • Pedram Honarpisheh,
  • Gabriela Delevati Colpo,
  • Hilda W. Ahnstedt,
  • Lucy Couture,
  • Shivanki Juneja,
  • Glenda Torres,
  • Guadalupe J. Ortiz,
  • James Sollome,
  • Natalie Tabor,
  • Bhanu P. Ganesh,
  • H. Alex Choi,
  • Fudong Liu,
  • Louise D. McCullough,
  • Andrey S. Tsvetkov

DOI
https://doi.org/10.1038/s41419-022-04861-2
Journal volume & issue
Vol. 13, no. 5
pp. 1 – 12

Abstract

Read online

Abstract Coronavirus disease (COVID-19), caused by SARS-CoV-2, leads to symptoms ranging from asymptomatic disease to death. Although males are more susceptible to severe symptoms and higher mortality due to COVID-19, patient sex has rarely been examined. Sex-associated metabolic changes may implicate novel biomarkers and therapeutic targets to treat COVID-19. Here, using serum samples, we performed global metabolomic analyses of uninfected and SARS-CoV-2-positive male and female patients with severe COVID-19. Key metabolic pathways that demonstrated robust sex differences in COVID-19 groups, but not in controls, involved lipid metabolism, pentose pathway, bile acid metabolism, and microbiome-related metabolism of aromatic amino acids, including tryptophan and tyrosine. Unsupervised statistical analysis showed a profound sexual dimorphism in correlations between patient-specific clinical parameters and their global metabolic profiles. Identification of sex-specific metabolic changes in severe COVID-19 patients is an important knowledge source for researchers striving for development of potential sex-associated biomarkers and druggable targets for COVID-19 patients.